UI081

UI081 is a small molecule drug candidate being developed by Korea United Pharm as a lipid-modifying agent for the treatment of dyslipidemia and other lipid metabolism disorders. It is classified as an Incrementally Modified Drug (IMD), a category in which Korea United Pharm specializes by creating novel fixed-dose combinations (FDCs) or improved formulations of existing pharmaceutical ingredients. UI081 is a new combination therapy, likely pairing a statin (HMG-CoA reductase inhibitor) with another lipid-lowering agent such as a cholesterol absorption inhibitor (e.g., ezetimibe), a PPAR-alpha agonist (e.g., a fibrate), or omega-3 fatty acids to provide synergistic effects in managing cholesterol and triglyceride levels. As of early 2024, UI081 is in the formulation and preclinical stages of development, with plans for future clinical advancement in South Korea.